Exscientia Inc. (EXAI) - יחס מחיר להכנסות חזויות

Exscientia plc (EXAI) is a pioneer in applying AI to drug design for Big Pharma and startups. The projected P/S ratio helps assess the asset's value relative to expected sales, where the parameter value is 29.10. The company's prospects rely on clinical trials of oncology drugs and the use of neural networks to accelerate R&D in the US and UK in collaboration with global pharma behemoths.

Exscientia plc (EXAI) is consolidating the digital drug discovery market through a merger with an AI platform, which radically optimizes R&D costs. The ratio of market capitalization to projected revenue determines the value of future sales, allowing investors to assess whether the asset is overheated or trading at a discount by tracking the company's P/S expectations for a timely entry into the position.